Search studies
1 study found
FAIR evaluation
Study types
- observational (1)
- 3D cell cultures (0)
- Brightfield microscopy (0)
- Clinical trial (0)
- Clinical trial NCIT:C71104 (0)
- Drug discovery (0)
- Drug repurposing (0)
- MiRCOVID participants` samples and data for COVIRNA (0)
- PREDI-COVID participants` samples and data for COVIRNA (0)
- PROVID cohort of hospitalized COVID-19 patients (0)
Organisms
Disease
ABI-RA
Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.
1
- Types: Observational
